Search Results

Glenmark Pharmaceuticals Inc. is voluntarily recalling 114 batches of Potassium Chloride Extended-Release Capsules, USP 10 mEq K, to the consumer level.

Ichnos Sciences Inc. (Ichnos), a global, fully integrated, clinical-stage biotech company and Glenmark Pharmaceuticals Ltd. (Glenmark), a leading, research-driven, global pharmaceutical company, today announced the launch of their alliance – Ichnos Glenmark Innovation – to accelerate new drug discovery in cancer treatment.

Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage biotech company developing multispecifics™ in oncology, and Glenmark Pharmaceuticals Ltd., shared preclinical data for its oncology asset ISB 2001 during the oral presentation at the annual American Association for Cancer Research (AACR) 2024.

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched their Fingolimod Capsules, 0.5 mg, the generic version of Gilenya ®1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex® 1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.

Glenmark Specialty SA, the subsidiary of Glenmark Pharmaceuticals Ltd., an innovation-driven, global pharmaceuticals company received acceptance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application for GRC 54276 to proceed with a Phase 1/2, first-in-human, clinical study of GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas.